



January 8, 2015

## **Alder BioPharmaceuticals Announces Pricing of Follow-On Offering**

BOTHELL, Wash., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq:ALDR), a clinical-stage biopharmaceutical company, announced today the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a price to the public of \$29.50 per share. Alder is offering all of the shares of common stock. In addition, Alder has granted the underwriters a 30-day option to purchase up to 900,000 additional shares of common stock at the public offering price. The offering is expected to close on January 13, 2015, subject to customary closing conditions.

Credit Suisse, Leerink Partners and Wells Fargo Securities are acting as joint book-running managers for the offering. Sanford C. Bernstein is acting as co-manager for the offering.

The Securities and Exchange Commission declared effective a registration statement relating to the offering of these securities on January 8, 2015. The offering is being made only by means of a prospectus, which is part of the effective registration statement. A copy of the prospectus relating to the offering may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York, 10010, and by phone at 1-800-221-1037 or by email at [newyork.prospectus@credit-suisse.com](mailto:newyork.prospectus@credit-suisse.com); from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, and by phone at 1-800-808-7525 or by email at [syndicate@leerink.com](mailto:syndicate@leerink.com); or from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York, 10152, or by email at [cmclientsupport@wellsfargo.com](mailto:cmclientsupport@wellsfargo.com), or by phone at 1-800-326-5897.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

CONTACT: Media Contacts:

David Schull or Andrea Flynn, Ph.D.

Russo Partners

(212) 845-4271

(646) 942-5631

[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

[andrea.flynn@russopartnersllc.com](mailto:andrea.flynn@russopartnersllc.com)

Investor Relations Contacts:

Sarah McCabe

Stern Investor Relations, Inc.

(212) 362-1200

[sarah@sternir.com](mailto:sarah@sternir.com)